Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy

Emanuelle M. Rizk; Robyn D. Gartrell; Luke W. Barker; Camden L. Esancy; Grace G. Finkel; Darius D. Bordbar; Yvonne M. Saenger

doi:10.1016/j.hoc.2018.12.005

Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy

Emanuelle M. Rizk, Robyn D. Gartrell, Luke W. Barker, Camden L. Esancy, Grace G. Finkel, Darius D. Bordbar, Yvonne M. Saenger

Research output: Contribution to journal › Review article › peer-review

19 Scopus citations

Abstract

Immunotherapy has drastically improved the prognosis of many patients with cancer, but it can also lead to severe immune-related adverse events. Biomarkers, which are molecular markers that indicate a patient's disease outcome or a patient's response to treatment, are therefore crucial to helping clinicians weigh the potential benefits of immunotherapy against its potential toxicities. Immunohistochemistry (IHC) has thus far been a powerful technique for discovery and use of biomarkers such as CD8 ⁺ tumor-infiltrating lymphocytes. However, IHC has limited reproducibility. Thus, if more IHC-based biomarkers are to reach the clinic, refinement of the technique using multiplexing or automation is key.

Original language	English (US)
Pages (from-to)	291-299
Number of pages	9
Journal	Hematology/Oncology Clinics of North America
Volume	33
Issue number	2
DOIs	https://doi.org/10.1016/j.hoc.2018.12.005
State	Published - Apr 2019
Externally published	Yes

Keywords

Checkpoint inhibition
Immunohistochemistry
Immunotherapy
Predictive and prognostic biomarkers

ASJC Scopus subject areas

Hematology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.hoc.2018.12.005

Cite this

@article{b7af228bc7e048488796adba9b5365fc,

title = "Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy",

abstract = " Immunotherapy has drastically improved the prognosis of many patients with cancer, but it can also lead to severe immune-related adverse events. Biomarkers, which are molecular markers that indicate a patient's disease outcome or a patient's response to treatment, are therefore crucial to helping clinicians weigh the potential benefits of immunotherapy against its potential toxicities. Immunohistochemistry (IHC) has thus far been a powerful technique for discovery and use of biomarkers such as CD8 + tumor-infiltrating lymphocytes. However, IHC has limited reproducibility. Thus, if more IHC-based biomarkers are to reach the clinic, refinement of the technique using multiplexing or automation is key.",

keywords = "Checkpoint inhibition, Immunohistochemistry, Immunotherapy, Predictive and prognostic biomarkers",

author = "Rizk, {Emanuelle M.} and Gartrell, {Robyn D.} and Barker, {Luke W.} and Esancy, {Camden L.} and Finkel, {Grace G.} and Bordbar, {Darius D.} and Saenger, {Yvonne M.}",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2019",

month = apr,

doi = "10.1016/j.hoc.2018.12.005",

language = "English (US)",

volume = "33",

pages = "291--299",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy

AU - Rizk, Emanuelle M.

AU - Gartrell, Robyn D.

AU - Barker, Luke W.

AU - Esancy, Camden L.

AU - Finkel, Grace G.

AU - Bordbar, Darius D.

AU - Saenger, Yvonne M.

PY - 2019/4

Y1 - 2019/4

N2 - Immunotherapy has drastically improved the prognosis of many patients with cancer, but it can also lead to severe immune-related adverse events. Biomarkers, which are molecular markers that indicate a patient's disease outcome or a patient's response to treatment, are therefore crucial to helping clinicians weigh the potential benefits of immunotherapy against its potential toxicities. Immunohistochemistry (IHC) has thus far been a powerful technique for discovery and use of biomarkers such as CD8 + tumor-infiltrating lymphocytes. However, IHC has limited reproducibility. Thus, if more IHC-based biomarkers are to reach the clinic, refinement of the technique using multiplexing or automation is key.

AB - Immunotherapy has drastically improved the prognosis of many patients with cancer, but it can also lead to severe immune-related adverse events. Biomarkers, which are molecular markers that indicate a patient's disease outcome or a patient's response to treatment, are therefore crucial to helping clinicians weigh the potential benefits of immunotherapy against its potential toxicities. Immunohistochemistry (IHC) has thus far been a powerful technique for discovery and use of biomarkers such as CD8 + tumor-infiltrating lymphocytes. However, IHC has limited reproducibility. Thus, if more IHC-based biomarkers are to reach the clinic, refinement of the technique using multiplexing or automation is key.

KW - Checkpoint inhibition

KW - Immunohistochemistry

KW - Immunotherapy

KW - Predictive and prognostic biomarkers

UR - http://www.scopus.com/inward/record.url?scp=85060116071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060116071&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2018.12.005

DO - 10.1016/j.hoc.2018.12.005

M3 - Review article

C2 - 30833001

AN - SCOPUS:85060116071

SN - 0889-8588

VL - 33

SP - 291

EP - 299

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

IS - 2

ER -

Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this